肿瘤放疗联合免疫治疗之回顾与展望

Review and Prospect of Radiotherapy Combined with Immunotherapy for Tumors

近年来肿瘤免疫检查点抑制剂为核心的免疫治疗策略以其较低的毒性和在经筛选人群中优秀的疗效,为抗肿瘤治疗带来了新的发展方向和希望。但是单纯的免疫治疗还是面临有效率人群有限、瘤种应用范围不足的困境。放疗因为其特殊肿瘤杀伤机制和免疫环境影响,与免疫治疗联合应用,有望以“1+1>2”的优势,获得更好的临床疗效和更大的应用范围。笔者回顾了放免联合的理论基础与研究,相关临床研究热点成果,提出了放免联合策略的优化方向,并对未来面临的挑战和发展方向提出了总结和展望。随着研究的不断进行,放疗与免疫治疗的联合将更加规范、安全与精准,为中国患者带来更加可靠的临床指导与全新的治疗格局。

In recent years, immune checkpoint inhibitors with low toxicity and excellent efficacy, which serves as a core of immunotherapy strategies, have brought new prospect for anti-tumor therapies. However, the solo use of immunotherapy is only effective in limited populations and applicable for not all tumor species. Because of its special tumor-killing mechanisms and immune environment, radiation combined with immunotherapy is expected to obtain more than double advantages in clinical efficacy and application scope. We reviewed the theoretical basis of the combination of radiation and immunotherapy, relevant clinical research hotspots, and proposed the optimization direction of the joint strategy, as well as the prospect of future challenges and development. With continuous development of research, the combination of radiotherapy and immunotherapy will be more standardized, safe and accurate, bringing more reliable clinical guidance and a new treatment pattern for Chinese patients.